DISITAMAB VEDOTIN COMBINED WITH PYROTINIB AS SALVAGE TREATMENT IN HER-2-AMPLIFIED TREATMENT REFRACTORY METASTATIC COLORECTAL CANCER: A CASE REPORT

Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report

BackgroundHuman epidermal growth factor receptor 2 (HER-2) amplification has Alter been identified in approximately 3% of patients with metastatic colorectal cancer (mCRC).Owing to the lack of established anti-ERBB2 therapeutic approaches, mCRC patients with Her-2 amplification rarely receive targeted treatments.Moreover, conventional chemotherapy

read more

High-level fluorescence labeling of gram-positive pathogens.

Fluorescence labeling of bacterial pathogens has a broad range of interesting applications including the observation of living bacteria within host cells.We constructed a novel vector based on the E.coli streptococcal shuttle plasmid pAT28 that can propagate in numerous bacterial species from different genera.The plasmid harbors a promoterless copy

read more